Kinjal Bhadresha

Kinjal Bhadresha

Auto-generated profile, based on publicly available information

Kinjal Bhadresha

National Cancer Institute

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2025 in Cancer Research Communications
Verified
Journal Article
Open access
BBBenjamin C. Brim
Benjamin C. Brim
ALAndres F. Leon
Andres F. Leon
EBErica L. Beatson
Erica L. Beatson
JKJessica D. Kindrick
Jessica D. Kindrick
KBKinjal Bhadresha
Kinjal Bhadresha
William FiggWilliam Figg
William Figg
There is an unmet need to develop novel treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC). Patients often develop resistance to next-generation hormonal therapies that target the androgen receptor (AR) axis (e.g., abiraterone and enzalutamide). A splice variant of AR, AR-V7, is associated with resistance to these inhibitors as well as mCRPC progression and poor prognoses. We embarked upon a high-throughput screen to identify synergistic combinations of targeted therapies using two CRPC cell lines, LNCaP95 and VCaP-CR. Combinations targeting BCL2L1 (Bcl-xL) (A-1331852 and navitoclax) and MCL1 (S63845) synergistically decreased cell viability and induced apoptotic activity via cleavage of PARP, caspase 3, and caspase 7 across AR-V7–expressing CRPC cell lines (LNCaP95, VCaP-CR, and 22Rv1) and a patient-derived organoid model (LuCaP 167CR). We also explored the use of a Bcl-xL–specific proteolysis-targeting chimera degrader (PROTAC) to minimize platelet toxicity associated with Bcl-xL inhibitors. We showed similar synergistic efficacy with the Bcl-xL–targeting PROTAC in combination with S63845 in the three-dimensional spheroid models. Our findings support further preclinical development of Bcl-xL and Mcl-1 inhibitors for mCRPC. Significance: Using an unbiased, combinatorial, high-throughput drug screen, we identified the combination of co-targeting Bcl-xL and Mcl-1 to be highly synergistic across AR-V7–expressing CRPC models. We showed efficacy in higher-order models through validation across in vitro models spanning two-dimensional cell culture, three-dimensional cell culture, and a patient-derived organoid model. These findings identify a promising therapeutic strategy for patients with AR-V7–expressing CRPC.

9 January 2026 in medRxiv
Verified
Preprint
Open access
PDF file
CLChennan Li
Chennan Li
JYJuanJuan Yin
JuanJuan Yin
MAMelissa L. Abel
Melissa L. Abel
DSDana S. Vargas Solivan
Dana S. Vargas Solivan
KBKinjal Bhadresha
Kinjal Bhadresha
ASAdam G. Sowalsky
Adam G. Sowalsky
Aggressive variant prostate cancer (AVPC) is a lethal subtype of prostate cancer characterized by its androgen independence, resistance to chemotherapy, and display of neuroendocrine features which can emerge either de novo or via transformation after a prior diagnosis of adenocarcinoma. The poor clinical outcomes in patients with AVPC are associated with its profound molecular heterogeneity. In this study, we analyzed 23 consecutive AVPC cases treated at a dedicated small-cell clinic (2017-2025) using clinicogenomic and transcriptomic profiling. Transformed AVPC exhibited significantly shorter overall survival times than de novo AVPC (11.8 vs 26.0 months, P < 0.001). Integrative genomic analyses identified residual androgen signaling in subsets of cases harboring neuroendocrine lineage programs, highlighting a decoupling of lineage identity and morphology. To facilitate mechanistic and pharmacologic studies, we established NCI-LYM-1, a patient-derived organoid/PDX from an AR-negative, ASCL1+/SYP+ lymph node metastasis, which faithfully recapitulates the donor tumor's molecular and phenotypic features. Short- and long-read whole-genome sequencing combined with optical genome mapping identified biallelic inactivation of PTEN, TP53, RB1 and BRCA2 as potential drivers, demonstrating clonal concordance with circulating tumor DNA from the original patient donor. Pathway and perturbation analyses suggested that NCI-LYM-1 harbored a strong dependency on apoptotic pathways, which was confirmed by in vitro organoid testing with the BCL-2/BCL-xL inhibitor navitoclax (IC50: 0.27 μM) and the MCL-1 inhibitor AZD-5991 (IC50: 0.060 μM). Overall, NCI&-LYM-1 recapitulates the clinical aggressiveness and heterogeneity of AVPC, providing a tractable platform to identify novel precision therapies.

21 August 2025
Verified
Other
Open access
BBBenjamin C. Brim
Benjamin C. Brim
ALAndres F. Leon
Andres F. Leon
EBErica L. Beatson
Erica L. Beatson
JKJessica D. Kindrick
Jessica D. Kindrick
KBKinjal Bhadresha
Kinjal Bhadresha
William FiggWilliam Figg
William Figg
Figure S5 shows that A-1331852, Navitoclax, and S63845 have similar potency across 2D culture and 3D spheroids.

21 August 2025
Verified
Other
Open access
BBBenjamin C. Brim
Benjamin C. Brim
ALAndres F. Leon
Andres F. Leon
EBErica L. Beatson
Erica L. Beatson
JKJessica D. Kindrick
Jessica D. Kindrick
KBKinjal Bhadresha
Kinjal Bhadresha
William FiggWilliam Figg
William Figg
Identification of Synergistic BH3-mimetic–based combinations in LNCaP95 and VCaP-CR Cells. A, Correlation plot depicting DBSumNeg (synergy score) for drugs that pair well with S63845 across LNCaP95 and VCaP-CR lines. B, All pairings of BH3 mimetics ranked by average DBSumNeg across LNCaP95 and VCaP-CR lines. C to F, Example drug screen data from A-1331852 paired with S63845 in VCaP-CR (C and D) and LNCaP95 (E and F) cells using CellTiter-Glo to measure response. Cell viability (C and E) and Bliss synergy were calculated for each point. Z-plots depict Bliss synergy score at each concentration (D and F). G, Patient mRNA sequencing data from the SU2C 2019 cohort of patients with mCRPC reveals the expression of AR, BCL2, Bcl-xL, and MCL1. Cohort expression was displayed utilizing GraphPad Prism 10, and data are expressed as fragments per kilobase of transcript per million mapped reads (FPKM).

21 August 2025
Verified
Other
Open access
PDF file
BBBenjamin C. Brim
Benjamin C. Brim
ALAndres F. Leon
Andres F. Leon
EBErica L. Beatson
Erica L. Beatson
JKJessica D. Kindrick
Jessica D. Kindrick
KBKinjal Bhadresha
Kinjal Bhadresha
William FiggWilliam Figg
William Figg
Table S1 depicts the IC50 values of BH3 mimetics as single agents in 2D models.

21 August 2025
Verified
Other
Open access
BBBenjamin C. Brim
Benjamin C. Brim
ALAndres F. Leon
Andres F. Leon
EBErica L. Beatson
Erica L. Beatson
JKJessica D. Kindrick
Jessica D. Kindrick
KBKinjal Bhadresha
Kinjal Bhadresha
William FiggWilliam Figg
William Figg
Figure S4 shows protein level changes after 24 hours of treatment with DMSO, A-1331852, S63845, or the combination of A-1331852 and S63845.